“New Depression Meds Not Effective Generally, But Drug Companies Insist Otherwise: Study”
The International Business Times covers a new study showing “trials for new antidepressant medications may not be applicable to the population at large.” “The finding, published in the Mayo Clinic Proceedings, shows recent trials are less generalizable than the prior studies, as researchers excluded most depressed patients from drug company-sponsored treatment studies.”
Concern that Generic Antipsychotics May Lead to Rise in Off-label Prescribing to Children
Healthline reports that as five second-generation antipsychotics (SGAs) lose patent protection, Medicaid expenditures for antipsychotics are projected to be cut in half over the next five years. But some worry that the decrease in spending may lead policymakers to lift existing restrictions on antipsychotics at a time when most SGAs are prescribed to children for off-label reasons.
Majority of Youth Prescribed Antipsychotics Have No Psychiatric Diagnosis
The majority of children, adolescents and young adults prescribed antipsychotic medications have not been diagnosed with a mental disorder, according to a recent study published in JAMA Psychiatry.
Call to Ban “Low Testosterone” Ads as “Disease-mongering”
An editorial in the Journal of the American Geriatrics Society has called for a ban on advertisements about testosterone replacement therapy, and the FDA has issued warnings about the practice.
PsychRights Seeking Plaintiffs to Sue Physicians for Off-label Prescribing to Children
The Law Project for Psychiatric Rights is eager to provide advice or assistance to US citizens who may wish to sue their physicians for prescribing off-label psychiatric drugs to children, said lawyer James Gottstein in an interview with Mad In America.
